Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novavax COVID-19 Vaccine in People Living With HIV
NCT05112848Phase 2Completed
- Sponsor
- Novavax
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Novavax. Primary endpoints: Number of participants with unsolicited adverse events at Day 180, Number of participants with solicited systemic adverse events at Day 70 and 4 more. Started Feb 2022; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05112848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112848.